Physician profile
Anthony E Good
NPI 1093908774
$3,382.73
in general payments reported to CMS, 2019-2025
26 companies · $1,132 in 2025
The $1,132 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $57.90 · 2022: $1,045 · 2023: $543 · 2024: $605 · 2025: $1,132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,279.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $479.13 | 2022 | |
| Boston Scientific Corporation | $381.62 | 2022-2025 | Watchman Flx, Watchman |
| Jazz Pharmaceuticals INC. | $352.53 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $268.40 | 2023-2025 | Uzedy, Austedo, Austedo Xr |
| Inari Medical, INC. | $221.49 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Alexion Pharmaceuticals, INC. | $162.61 | 2024 | Ultomiris |
| Vifor Pharma, INC. | $136.50 | 2021-2024 | Veltassa |
| Travere Therapeutics, INC. | $135.82 | 2022-2024 | |
| Agios Pharmaceuticals, INC. | $133.35 | 2025 | Pyrukynd |
| Corium, LLC | $130.37 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $116.65 | 2022-2025 | |
| Lilly USA, LLC | $115.00 | 2025 | Mounjaro |
| Impel Pharmaceuticals INC. | $113.40 | 2023 | Trudhesa |
| Incyte Corporation | $104.51 | 2022 | |
| Neurelis, INC. | $91.82 | 2023 | Valtoco |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $69.19 | 2025 | |
| Phathom Pharmaceuticals, INC. | $67.77 | 2025 | Voquezna |
| Verona Pharma, INC. | $62.43 | 2025 | Ohtuvayre |
| Tactile Systems Technology INC | $47.67 | 2024 | Entre Plus, Flexitouch Plus |
| Abbvie INC. | $39.53 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $35.27 | 2022 | |
| Novo Nordisk INC | $30.80 | 2022 | |
| Corcept Therapeutics | $30.52 | 2024 | Korlym |
| Ardelyx, INC. | $24.15 | 2024 | Ibsrela |
| Akebia Therapeutics INC | $17.92 | 2021 | |
| Resmed Corp | $14.28 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Good listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.